Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MK-1167 Administered to Patients With Alzheimer's Disease Receiving Stable Donepezil Treatment
Sponsor: Merck Sharp & Dohme LLC
This PHASE1 trial investigates Alzheimer's Disease and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 10 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
-
Sep 2025 — Nov 2025 [monthly]
Completed PHASE1
-
Oct 2024 — Sep 2025 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 5 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .